Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy

MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway

“…Moreover, MnSOD-positive patients who received cisplatin-based chemotherapy demonstrated poorer overall survival rates than MnSOD-negative patients (Supplementary Table 1). A consistent result was also reported by a previous study, which indicated that Bcl-2 expression might predict a poor outcome in locally advanced non-small-cell lung cancer patients who received cisplatin-based chemotherapy [25]. Therefore, we suggest that MnSOD might act as a therapeutic marker to predict drug response and outcome in lung adenocarcinoma patients who have received cisplatin-based chemotherapy.…”

Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy

“…The group studied most extensively for the impact of ERCC1 so far were patients with non-small cell lung cancer (NSCLC), though the studies differed substantially with regard to selection criteria such as adjuvant therapy versus palliative treatment or progressive disease [1][2][3]. The different methods used, mostly IHC and RT-PCR, and the heterogeneous patient collectives do not always allow comparison of results.…”

“…Among the specific markers investigated for their predictive value, the significance of ERCC1 (Excision repair cross-complementing rodent repair deficiency group 1) in ovarian carcinoma has received significant attention, analogous to non-small cell lung cancer [1][2][3][4][5][6][7][8][9]. Strongly positive ERCC1 immunohistochemistry (IHC) and a high level of ERCC1 mRNA are regarded as an indication for efficient repair of tumor DNA damaged by cytostatic agents, resulting in therapy resistance [10,11].…”

The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis

“…However, different studies in advanced NSCLC patients with the similar expression patterns of ERCC1 have yielded inconsistant results of platinum-based chemotherapy including several randomized trials investigating the benefit of platinum-based chemotherapy in advanced NSCLC patients with low/negative expression of ERCC1 [18][19][20]. Even studies using the same methods for detecting the expression of ERCC1, have yielded contradictory findings [18,21].…”